Modality
Fusion Protein
MOA
CDK2i
Target
PD-L1
Pathway
Wnt
UC
Development Pipeline
Preclinical
May 2025
→ Jul 2026
PreclinicalCurrent
NCT08494150
74 pts·UC
2025-05→2026-07·Terminated
74 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-07-234mo awayInterim· UC
Trial Timeline
Q3Q42026Q2Q3
Preclinical
Termina…
Catalysts
Interim
2026-07-23 · 4mo away
UC
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08494150 | Preclinical | UC | Terminated | 74 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 |